BJT-778

DRUG4 trials

Sponsors

Bluejay Therapeutics Inc.

Conditions

Chronic Hepatitis D InfectionChronic Hepatitis Delta Infection

Phase 2

A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)

Active, not recruitingCTIS2024-519063-18-00

Bluejay Therapeutics Inc.Chronic Hepatitis Delta Infection

Start: 2025-06-24Target: 30Updated: 2025-12-22

A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)

Not yet recruitingCTIS2025-522015-42-00

Bluejay Therapeutics Inc.Chronic Hepatitis D Infection

Target: 55Updated: 2026-02-05

Phase 3

A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

RecruitingCTIS2024-517167-23-00

Bluejay Therapeutics Inc.Chronic Hepatitis D Infection

Start: 2025-08-28Target: 141Updated: 2026-01-16

A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Not yet recruitingCTIS2025-522105-38-00

Bluejay Therapeutics Inc.Chronic Hepatitis Delta Infection

Target: 17Updated: 2026-01-07